FDA approves the first subcutaneous version of nivolumab, making PD-1 inhibitors available to new groups of patients.
On December 27, 2024, subcutaneous nivolumab (Opdivo Qvantig) was approved by the FDA in all previously approved adult solid ...
The FDA has approved Opdivo Qvantig (nivolumab and hyaluronidase-nvhy), a new subcutaneous injection formulation of Opdivo.
The U.S. Food and Drug Administration has approved Opdivo Qvantig (nivolumab and hyaluronidase-nvhy) injection for ...
On December 20, 2024, the FDA granted accelerated approval to the combination of encorafenib (Braftovi), cetuximab (Erbitux), ...
Almost exactly 10 years after the FDA’s initial FDA approval for Bristol Myers Squibb’s Opdivo as the first PD-1 inhibitor in ...
Opdivo Qvantig combines nivolumab, a programmed death receptor ... available as a solution for intravenous (IV) infusion. The approval of Opdivo Qvantig was supported by data from the randomized ...
Dr. Eric K. Singhi discusses the benefit of subcutaneous immunotherapy following the FDA approval of subcutaneous Opdivo for ...
Nivolumab biosimilar is under clinical development by Amgen and currently in Phase III for Metastatic Melanoma.
The US Food and Drug Administration (FDA) on Friday approved nivolumab and hyaluronidase-nvhy, under the trade name Opdivo ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback